KWM
NVO

Kanen Wealth Management’s Novo Nordisk NVO Stock Holding History

Kanen Wealth Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-75,500
Closed -$3.96M – 40
2025
Q4 		$3.96M Buy
+75,500
New +$3.86M 1.2% 19

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Kanen Wealth Management's NVO Position: Q1 2026 in Review

Kanen Wealth Management sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 75,500 shares — an estimated $3.96M sold.

Kanen Wealth Management first reported a position in NVO in Q4 2025 and held it in 1 quarter. The position peaked at $3.96M in Q4 2025. 1,270 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Kanen Wealth Management reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
  • Kanen Wealth Management sold 75,500 Novo Nordisk shares in Q1 2026, an estimated $3.96M.
  • Kanen Wealth Management first reported a position in Novo Nordisk in Q4 2025 and held it in 1 quarter.
  • Kanen Wealth Management's Novo Nordisk position peaked at $3.96M in Q4 2025.
  • 1,270 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Kanen Wealth Management's 13F filing for Q1 2026, filed 18 May 2026.